# Organ Preservation Market

> Organ Preservation Market Research Report By Solution (University of Wisconsin Solution, Custodial HTK, Collins Solution, Celsior Solution, Perfadex, Citrate Solution), By Preservation Techniques (Static Cold Storage, Dynamic Cold Storage) By Organ Type (Kidney, Liver, Heart, Lungs), By End User (Hospitals & Clinics, Organ Banks), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 6.7%
- **2025:** USD 358.6 Million
- **2035:** USD 685.8 Million
- **Key Players:** XVIVO Perfusion AB, TransMedics Group, Organ Recovery Systems (Lifeline Scientific), Bridge to Life Ltd., OrganOx Ltd., Paragonix Technologies (Getinge), Institut Georges Lopez (IGL), Preservation Solutions Inc.

**Report ID:** MRFR/HC/4615-CR · **Pages:** 169 · **Author:** Rahul Gotadki & Nidhi Mandole · **Last Updated:** August 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/organ-preservation-market-6073

---

## Market Summary

As per MRFR analysis, the Organ Preservation Market Size was estimated at 337.57 USD Million in 2024. The Organ Preservation industry is projected to grow from 357.21 USD Million in 2025 to 628.95 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 5.82% during the forecast period 2025 - 2035.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising end-stage organ failure prevalence | +1.5 | Global | Long-term (≥4 yr) | [5] |
| Machine perfusion adoption and DCD donor expansion | +1.6 | North America, Europe | Medium-term (2–4 yr) | [6] |
| Regulatory approvals and procedure reimbursement | +1.1 | North America | Short-term (≤2 yr) | [7] |
| Organ procurement organisation performance mandates | +0.8 | United States | Short-term (≤2 yr) | [1] |
| Long-distance and cross-border allocation logistics | +0.6 | Europe, Asia-Pacific | Medium-term (2–4 yr) | [8] |
| Emerging-market transplant infrastructure buildout | +0.5 | Asia-Pacific, MEA | Long-term (≥4 yr) | [9] |
| Xenotransplantation and viability-assessment research | +0.4 | Global | Long-term (≥4 yr) | [10] |

### Machine Perfusion Converts Discarded Organs Into Transplants

Once upon a time, donation following circulatory death was a marginal route. It is currently the engine for growth. About 40% of all deceased donations in the UK come from DCD donors, according to data [[3]](https://nhsbt.nhs.uk). This percentage would be clinically unmanageable without perfusion technology bridging the warm ischemic gap. The argument has been supported by randomized data: in European liver transplantation, hypothermic oxygenated perfusion trials showed significant decreases in non-anastomotic biliary strictures when compared to cold storage alone [[6]](https://nejm.org). Because perfusion cases have disposable costs per procedure that are several times more than those of a traditional preservation kit, every graft saved generates additional revenue for the organ preservation market.

4.2 Reimbursement Clarity Unlocked U.S. Capital Budgets

Adoption is gated through 2022 by payment structure rather than clinical proof. This was altered when organ acquisition cost centers and Medicare cost-report pass-through mechanisms allowed U.S. transplant programs to recover perfusion expenses, hence eliminating device consumables from the hospital's own margin line [[7]](https://cms.gov). Vendor installed bases increased between 2023 and 2024 as a result of program directors' prompt responses. In this scenario, the financial architecture is more important than list price: a perfusion episode costing between USD 65,000 and USD 90,000 per case can be justified if it is reimbursed at cost; otherwise, it cannot.

### Demographic Pressure Keeps the Waitlist Structurally Long

Kidney failure drives volume. The U.S. Renal Data System documents more than 800,000 Americans living with end-stage renal disease, while roughly 90,000 remain on the kidney waitlist at any point [[5]](https://usrds-adr.niddk.nih.gov). Diabetes and hypertension prevalence in Asia guarantees the same curve will steepen elsewhere. Waitlist mortality — over 6,000 U.S. deaths annually — is the political argument that keeps preservation funding insulated from broader hospital cost-cutting [[2]](https://optn.transplant.hrsa.gov).

### Procurement Reform Creates a Competitive Vendor Field

Consolidated procurement suppressed innovation for two decades. HRSA's decision to break the OPTN contract into modular awards, alongside CMS's donation-rate and transplantation-rate performance metrics for organ procurement organisations, forces OPOs to demonstrate measurable improvement or face decertification [[1]](https://hrsa.gov). Underperforming OPOs now buy technology defensively, which converts a policy mandate into a procurement cycle across the Organ Preservation Market.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| High capital and per-case cost of perfusion platforms | −1.2 | Global | Short-term (≤2 yr) | [11] |
| Structural donor pool ceiling | −0.9 | Global | Long-term (≥4 yr) | [2] |
| Reimbursement gaps outside the United States | −0.7 | Europe, Asia-Pacific | Medium-term (2–4 yr) | [12] |
| Clinical inertia and entrenched cold-storage protocols | −0.6 | Global | Medium-term (2–4 yr) | [6] |
| Fragmented device regulation and cold-chain compliance | −0.5 | Europe, MEA | Medium-term (2–4 yr) | [13] |

### Per-Case Economics Remain the Hard Ceiling

Cold storage was never as costly as perfusion. A single normothermic liver case can cost between $40,000 and $90,000 in disposables and service fees before personnel; a preservation solution bag costs a few hundred dollars [[11]](https://nice.org.uk). That expense falls directly on the budget of a transplant department outside of the U.S. pass-through system. Uncertain cost-effectiveness at present device pricing has been repeatedly noted by health technology evaluation authorities, which slows tender approvals across public systems and limits penetration in the mid-tier centers of the organ preservation market.

### Donors, Not Technology, Set the Volume Limit

Although it cannot produce new donors, preservation increases yield per donor. According to data, there are about 170,000 solid organ transplants performed each year globally, compared to an estimated need that is several times higher [[14]](https://transplant-observatory.org). While several Asian systems are still in the single digits, Spain leads with more than 50 deceased donors per million people [[9]](https://notto.mohfw.gov.in). Regardless of how well preservation improves, the addressable procedure base increases in the low single digits unless consent frameworks and ICU referral paths change.

### Protocol Change Is Slower Than Evidence

Surgeons trust what they trained on. Even where trial data favour perfusion, adoption requires retraining recovery teams, rewriting allocation timing, and accepting new failure modes during transport. That transition typically runs 18–36 months per centre, and smaller programmes performing fewer than 50 transplants annually often never reach the case volume that justifies the learning curve [[6]](https://nejm.org).

## Opportunities

## Organ Preservation Market Opportunities

### Viability Assessment as a Billable Service

Perfusion generates data — lactate clearance, bile production, vascular resistance — that can turn a subjective accept/decline call into a measurable one. Vendors that package this as a decision-support service rather than a consumable capture recurring revenue and defend against device commoditisation.

### Emerging-Market Transplant Infrastructure

India performed over 18,000 transplants in 2023 under NOTTO coordination, with deceased donation still below one per million population [[9]](https://notto.mohfw.gov.in). Systems building capacity from scratch can leapfrog directly to perfusion-first protocols rather than retrofitting them, which favours vendors willing to price for volume rather than margin.

### Organ Repair and Reconditioning

Ex vivo organ storage is evolving into ex vivo therapy — delivering thrombolytics, antivirals or gene-modifying agents to a graft in transit. Lung reconditioning protocols already demonstrate this, and hepatitis C-positive organs are now routinely transplanted following direct-acting antiviral pathways [[10]](https://fda.gov).

### Registry Data Monetisation and Outcome-Linked Contracting

Device fleets generate longitudinal perfusion telemetry linked to graft survival. Vendors can license de-identified outcome datasets to payers and pharmaceutical partners, or shift to risk-shared contracts where a portion of the fee is contingent on 12-month graft function.

### Xenotransplantation Preservation Protocols

FDA-authorised expanded-access xenotransplant procedures using gene-edited porcine kidneys have created a preservation category that does not yet have a standard [[10]](https://fda.gov). Whoever defines the perfusion protocol for xenografts will hold a durable position in the Organ Preservation Market if the modality reaches clinical scale after 2032.

## Future Outlook

## Organ Preservation Market Future Outlook

### Algorithmic Organ Acceptance

Decision support will absorb the accept/decline judgement that currently drives discard. Roughly 20% of recovered U.S. kidneys are discarded annually, and models trained on perfusion telemetry plus donor characteristics have shown they can identify a meaningful fraction of those as safely transplantable [[2]](https://optn.transplant.hrsa.gov). Expect regulatory scrutiny of these models as clinical decision software by the late 2020s.

### Service Economics Replace Product Economics

Vendors are migrating from selling boxes to selling procedures. The National [Organ Care System](https://www.marketresearchfuture.com/reports/organ-care-system-market-43258) model — where the vendor supplies device, disposables and a travelling clinical team as a bundled per-case fee — has proven that transplant centres will outsource operational complexity [[16]](https://sec.gov). Recurring per-case revenue should exceed hardware revenue across the Organ Preservation Market before 2030.

### Normothermic Regional Perfusion Standardises

In-situ perfusion of the donor before recovery is spreading quickly through European and U.S. cardiac programmes because it is cheaper than ex-situ machines and preserves multiple organs simultaneously. Ethical review remains unsettled in several jurisdictions, and resolution of that debate will determine whether NRP complements or partially displaces device demand [[8]](https://eurotransplant.org).

### Supply Chain and Sustainability Scrutiny

Charter aviation for organ transport carries both cost and carbon consequences, and transplant networks are beginning to measure it. Longer safe preservation windows enable ground and scheduled-air routing, cutting per-case logistics spend that can exceed USD 30,000 for distant cardiac recoveries [[8]](https://eurotransplant.org). Sustainability reporting will increasingly be a tender criterion in European public procurement.

## Segment Insights

## Organ Preservation Market Segmentation

### By Technique

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Static Cold Storage (SCS) | 52.4% share | Cost, simplicity, standard-criteria donors |
| Hypothermic Machine Perfusion (HMP) | USD 108.2 Million | Kidney DCD grafts and delayed graft function reduction |
| Normothermic Machine Perfusion (NMP) | 9.8% CAGR | Liver and cardiac viability assessment |
| Other Techniques | 4.9% share | Hypothermic oxygenated and regional perfusion |

Cold storage is not dying; it is being confined. For standard-criteria kidney and low-risk liver grafts recovered within a short transport radius, nothing beats it on cost. What has changed is the boundary — marginal grafts, extended criteria donors and long-haul recoveries now route to machine perfusion by default in high-volume centres. Normothermic technique is the growth pole of the Organ Preservation Market because it is the only approach that lets a surgeon test function before implanting rather than after.

### By Preservation Solution

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| University of Wisconsin (UW) Solution | 38.6% share | Abdominal organ gold standard |
| Custodiol HTK | USD 86.4 Million | Low viscosity, cardiac and multi-organ use |
| Celsior | 13.7% share | Thoracic organ preference in Europe |
| Perfadex | 9.8% share | Lung-specific preservation |
| Others | 6.1% CAGR | Institutional and regional formulations |

UW solution has held its position since the late 1980s largely on inertia and evidence depth. However, HTK has taken share in cardiac and paediatric applications where its lower viscosity and single-flush protocol reduce recovery time. Pricing in this segment is under pressure from generic and regional formulations, particularly in Asia-Pacific tenders.

### By Product Type

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Preservation Solutions | 46.3% share | Universal use across all techniques |
| Machine Perfusion Systems | 11.2% CAGR | Device installed base and per-case disposables |
| Transport and Storage Consumables | USD 67.8 Million | Cold-chain compliance and tracking requirements |

Solutions still generate the largest revenue slice, but they are a low-margin, price-eroding category. Perfusion systems invert that profile: high acquisition cost, high recurring disposable attach rate, and meaningful switching friction once a centre trains its team. Consumables and validated shipper containers form the quiet third leg, growing steadily as chain-of-custody documentation requirements tighten.

### By Organ Type

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Kidneys | 41.2% share | Highest global transplant volume |
| Liver | 8.1% CAGR | Normothermic viability assessment adoption |
| Heart | USD 46.3 Million | DCD cardiac recovery expansion |
| Lung | 11.4% share | Ex-vivo reconditioning protocols |
| Pancreas | 4.6% share | Islet and whole-organ procedures |
| Others | 5.4% CAGR | Intestinal and multi-visceral grafts |

Kidneys dominate in count, but liver and heart dominate on revenue per case — a single cardiac perfusion episode can carry twenty times the preservation spend of a routine kidney recovery. The most consequential recent shift is DCD heart transplantation, which was clinically impossible at scale before perfusion technology and now accounts for a growing share of cardiac programmes' volume growth in the U.S., UK and Australia [[10]](https://fda.gov).

### By End User

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Transplant Centers | USD 160.7 Million | Direct procedural ownership and capital budgets |
| Hospitals | 33.6% share | General surgical and recovery infrastructure |
| Organ Procurement Organizations | 9.4% CAGR | CMS performance mandates and recovery logistics |
| Research Institutes and Specialty Clinics | 6.9% share | Protocol development and xenotransplant research |

Transplant centres control the purchase decision in nearly every market. However, organ procurement organisations are the fastest-growing buyer class because performance regulation has given them both the obligation and the budget to invest in recovery technology [[1]](https://hrsa.gov).

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 41.5% share | OPTN modernisation, DCD expansion, perfusion reimbursement |
| Europe | USD 99.7 Million | Opt-out consent, cross-border allocation, HTA-driven tenders |
| Asia-Pacific | 8.9% CAGR | Donor registry buildout, domestic device manufacturing |
| South America | 5.4% share | Public transplant funding, Brazilian SUS network expansion |
| Middle East & Africa | USD 14.3 Million | Medical tourism hubs, national transplant programmes |
| Total | USD 358.6 Million | — |

North America leads the Organ Preservation Market on absolute revenue, but the growth story sits in Asia-Pacific, where transplant infrastructure spending is compounding from a low base.

### North America

| Country | Metric | Key Driver |
| --- | --- | --- |
| US | 87.4% of regional revenue | Highest global transplant volume and cost pass-through |
| Canada | USD 12.9 Million | Provincial donation coordination reform |
| Mexico | 6.2% CAGR | IMSS transplant capacity investment |

The United States performed more than 46,000 transplants in 2023, its twelfth consecutive record year, and that volume gives American programmes the case density to amortise perfusion capital quickly [[2]](https://optn.transplant.hrsa.gov). CMS performance metrics have made OPO underperformance financially consequential, while HRSA's contract restructuring introduced competitive vendor access to a network that had been single-sourced since 1986 [[1]](https://hrsa.gov). Canada moves more slowly, constrained by provincial fragmentation.

### Europe

| Country | Metric | Key Driver |
| --- | --- | --- |
| Germany | 19.8% of regional revenue | Eurotransplant allocation, DSO reform pressure |
| UK | USD 17.4 Million | Opt-out consent and high DCD share |
| France | 14.1% of regional revenue | Agence de la biomédecine national plan |
| Italy | 6.8% CAGR | CNT regional network investment |
| Spain | USD 13.2 Million | World-leading donation rate under ONT |
| Nordic Countries | 7.9% of regional revenue | Scandiatransplant coordination |
| Russia | 4.3% of regional revenue | Federal transplant centre expansion |
| Rest of Europe | USD 9.1 Million | Cross-border allocation agreements |

Spain sustains the highest deceased donation rate in the world at above 48 donors per million population, a result of ICU-embedded coordinators rather than technology alone [[9]](https://notto.mohfw.gov.in). Britain's opt-out legislation, in force in England since 2020 and Scotland since 2021, lifted consent rates but pushed a larger share of donation into the DCD pathway, which mechanically raises perfusion demand [[3]](https://nhsbt.nhs.uk). Germany remains the region's structural underperformer on donation rate, and reform there represents the single largest untapped European volume pool.

### Asia-Pacific

| Country | Metric | Key Driver |
| --- | --- | --- |
| China | 31.6% of regional revenue | National voluntary donation system scale-up |
| India | 11.4% CAGR | NOTTO coordination and private hospital capacity |
| Japan | USD 14.8 Million | Ageing population and living-donor dominance |
| South Korea | 12.7% of regional revenue | KONOS registry and government funding |
| ASEAN | USD 8.6 Million | Thailand and Singapore transplant hubs |
| Rest of Asia-Pacific | 8.4% CAGR | Australia and New Zealand programme growth |

China's transition to a fully voluntary citizen donation system since 2015 has produced steady annual growth in deceased donation, and domestic device manufacturers are now entering preservation categories at price points Western vendors cannot match [[15]](https://codac.org.cn). India presents the sharpest asymmetry: enormous clinical need, world-class private transplant centres, and a deceased donation rate under one per million [[9]](https://notto.mohfw.gov.in). Japan's constraint is cultural rather than economic, with living donation still accounting for the majority of kidney and liver cases.

### South America

| Country | Metric | Key Driver |
| --- | --- | --- |
| Brazil | 68.4% of regional revenue | SUS-funded national transplant system |
| Argentina | USD 3.9 Million | INCUCAI presumed-consent law |
| Rest of South America | 7.6% CAGR | Colombia and Chile programme expansion |

Brazil operates the largest publicly funded transplant programme in the world by procedure count, with the Sistema Único de Saúde covering all costs essentially [[17]](https://abto.org.br). That structure creates predictable, tender-driven demand for preservation solutions but limits uptake of premium perfusion hardware. Argentina's Ley Justina, which established presumed consent in 2018, lifted deceased donation meaningfully and remains the region's clearest policy template.

### Middle East & Africa

| Country | Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 34.2% of regional revenue | SCOT national programme and Vision 2030 health spend |
| UAE | USD 3.4 Million | Hayat programme and medical tourism positioning |
| South Africa | 14.6% of regional revenue | Established academic transplant centres |
| Egypt | 8.9% CAGR | Living-donor liver programme growth |
| Rest of MEA | USD 2.1 Million | Nascent national donation frameworks |

Saudi Arabia's Center for Organ Transplantation has built the region's most complete deceased-donor infrastructure, and Vision 2030 health capital allocations continue to fund tertiary transplant capacity [[18]](https://scot.gov.sa). The UAE launched its national programme in 2017 and positions transplant services as an export, competing for regional patients who previously travelled abroad. Across sub-Saharan Africa, dialysis access rather than transplantation remains the binding constraint.

## Competitive Benchmarking

## Competitive Benchmarking

Concentration is moderate. Market Research Future estimates a Herfindahl-Hirschman Index in the 850–1,000 band, with the top five vendors holding roughly 46–52% of global revenue. That structure reflects a bifurcated field: a small group of device innovators competing on clinical evidence, and a longer tail of solution manufacturers competing largely on tender price. Consolidation pressure is building as device firms seek consumable portfolios and solution firms seek device exposure. Vendors offering integrated organ transport solutions alongside perfusion hardware hold the strongest cross-sell position within the Organ Preservation Market.

| Company | Est. Revenue Share Range | Key Offerings for Organ Preservation Market | Strategic Positioning |
| --- | --- | --- | --- |
| XVIVO Perfusion AB | ~11–14% | Lung, heart, and abdominal perfusion systems; Perfadex Plus | Broadest multi-organ device portfolio |
| TransMedics Group | ~10–13% | Organ Care System (heart, lung, liver); national logistics network | Vertically integrated per-case service model |
| Organ Recovery Systems (Lifeline Scientific) | ~8–11% | LifePort kidney and liver transporters; SPS-1 solution | Installed-base leader in hypothermic kidney perfusion |
| Bridge to Life Ltd. | ~6–9% | Belzer UW solution; VitaSmart liver perfusion | Solution incumbent expanding into devices |
| OrganOx Ltd. | ~5–8% | Metra normothermic liver perfusion | Evidence-led liver specialist |
| Paragonix Technologies (Getinge) | ~4–7% | Organ-specific static transport and monitoring systems | Low-cost alternative to full perfusion |
| Institut Georges Lopez (IGL) | ~3–6% | IGL-1 and IGL-2 preservation solutions | European solution specialist |
| Preservation Solutions Inc. | ~3–5% | SPS-1 and machine perfusion solutions | Focused abdominal solution supplier |
| BioLifeSolutions | ~3–5% | HypoThermosol and biopreservation media | Adjacent cell-therapy crossover |
| Waters Medical Systems | ~2–4% | RM3 renal preservation systems | Legacy kidney perfusion installed base |
| 21st Century Medicine | ~1–3% | Vitrification and cryopreservation research media | Long-horizon research positioning |

## Recent News & Developments

## Recent News & Developments

- HRSA (March 2023): Announced the OPTN Modernization Initiative, ending the single-vendor contract structure and opening network components to competitive bidding, a decisive change in U.S. procurement dynamics [[1]](https://hrsa.gov)

- Getinge (August 2024): Completed acquisition of Paragonix Technologies, bringing organ transport hardware into a large-cap medtech distribution network [[19]](https://getinge.com)
- OrganOx (June 2024): Reported cumulative clinical use of its normothermic liver device across thousands of transplants worldwide, strengthening its evidence position with European HTA bodies [[20]](https://organox.com)
- XVIVO (February 2025): Expanded heart preservation commercialisation following clinical trial readouts supporting extended cardiac preservation windows [[21]](https://xvivogroup.com)
- FDA (December 2024): Cleared an expanded-access pathway for gene-edited porcine kidney xenotransplantation, creating early demand for xenograft-specific preservation protocols [[10]](https://fda.gov)
- NHS Blood and Transplant (April 2024): Published organ utilisation strategy targeting reduced discard rates, explicitly citing perfusion technology as an enabling intervention [[3]](https://nhsbt.nhs.uk)
- NOTTO India (November 2024): Issued revised national deceased donation guidelines aimed at raising the donation rate above two per million population by 2030 [[9]](https://notto.mohfw.gov.in)

## Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global Organ Preservation Market by technique, preservation solution, product type, organ type, end user and geography |
| Study Period | 2021–2035 (Historical 2021–2024; Base Year 2025; Forecast 2026–2035) |
| CAGR | 6.7% (2026–2035) |
| Market Size Checkpoints | USD 358.6 Million (2025); USD 382.6 Million (2026); USD 685.8 Million (2035) |
| Fastest Growing Segments | Normothermic Machine Perfusion (technique); Liver (organ type); Asia-Pacific (region) |
| Companies Profiled | 11 vendors including XVIVO Perfusion, TransMedics, Organ Recovery Systems, Bridge to Life, OrganOx, Paragonix Technologies |
| Valuation Currency | USD Million, constant 2025 prices |

## Frequently Asked Questions

**Q: What should investors evaluate before entering the Organ Preservation Market?**
A: Assess disposable attach rate per installed device rather than hardware unit sales. Recurring per-case consumable revenue determines long-run margin quality, and reimbursement pathway certainty in the buyer's country determines whether that revenue is collectable [7].

**Q: How do hospitals justify the capital cost of a machine perfusion programme?**
A: Justification rests on incremental transplants performed, not device utilisation. A programme adding fifteen otherwise-discarded grafts annually recovers capital through organ acquisition cost reporting and reduced dialysis burden [11].

**Q: Which procurement criteria matter most when comparing perfusion platforms?**
A: Prioritise organ coverage breadth, service response time, and clinical training support over headline device price. Single-organ platforms often force multi-vendor fleets, which multiplies staff training and maintenance overhead [19].

**Q: How does reimbursement policy shape adoption across the Organ Preservation Market?**
A: Where costs pass through to payers, adoption follows clinical evidence quickly. Where hospitals absorb costs internally, adoption stalls regardless of trial results — the clearest divide between U.S. and most European uptake curves [12].

**Q: What integration challenges do transplant centres face when adopting perfusion?**
A: Recovery teams must be retrained, allocation timing recalculated, and 24-hour perfusion coverage staffed. Most centres need eighteen to thirty-six months before perfusion becomes routine rather than exceptional [6].

**Q: Which emerging use cases could reshape the Organ Preservation Market after 2030?**
A: Ex-situ organ therapy — delivering drugs or gene therapies to a graft during transport — and xenograft-specific protocols are the two credible category expansions. Both remain pre-commercial today [10].

**Q: How does the regulatory pathway differ between preservation solutions and perfusion devices?**
A: Solutions are typically regulated as drugs or biologics requiring formulation-specific approval. Perfusion systems follow device pathways, and software-driven viability scoring increasingly triggers separate clinical decision support review [13].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/organ-preservation-market-6073*